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ABSTRACT 
 
 
Arginine and Conjugated Linoleic Acid Reduce Fat Mass in Rats. 
 
(May 2008) 
 
Jennifer Lynn Nall, B.S., Texas A&M University 
 
Chair of Advisory Committee:  Dr. Stephen B. Smith 
 
  
  
This experiment tested the hypothesis that the combination of dietary conjugated 
linoleic acid (CLA) plus arginine will decrease fat accumulation and increase muscle 
mass. Twenty-four male Sprague Dawley rats were assigned to treatments in a 2 x 2 
factorial design with six rats per treatment group (control: 2.55% alanine in drinking 
water + 1.5% canola oil; arginine: 1.25% arginine-HCl in drinking water + 1.5% canola 
oil; conjugated linoleic acid (CLA; mixed isomers): 2.55% alanine in drinking water + 
1.5% CLA; arginine + CLA: 1.25% arginine-HCl in drinking water + 1.5% CLA).  Rats 
fed arginine plus CLA had a higher daily intake of food (P = 0.02).  Rats fed arginine 
plus CLA had a higher average daily gain than rats fed only arginine or CLA. Arginine 
and CLA increased final body weights (P = 0.04,0.009). Abdominal fat mass (P = 0.08) 
and abdominal fat:lean body mass ratio (P = 0.03) were decreased by CLA but were 
unaffected by arginine.  Epididymal fat pad weight was unaffected by arginine or CLA 
(P > 0.55). CLA tended (P < 0.07) to decrease the plasma oleic/stearic acid ratio.  
Conversion of 14C-labeled glucose and palmitic acid to total lipids and CO2 in 
epididymal adipose tissue in vitro was unaffected by CLA.  Arginine decreased (P = 
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0.09) palmitic acid incorporation into total lipids in epididymal adipose tissue.  CLA 
plus arginine supplementation also reduced glucose incorporation into total lipid (P = 
0.20).  Arginine stimulated lipid synthesis from glucose in the absence of CLA, but had 
no effect in the presence of CLA.  In liver, arginine increased the rate of conversion of 
glucose to CO2 (P = 0.06).  Singly, arginine depressed plasma concentrations of all 
measured amino acids except serine.  CLA depressed all amino acids except cysteine.  
The combination of arginine plus CLA depressed the concentration of plasma arginine 
(P = 0.05).  The data indicate that arginine plus CLA decreases the fat/lean mass ratio, 
which may be due to effects on the metabolism of muscle, liver, and adipose tissue.   
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INTRODUCTION 
 
Obesity in humans is now considered endemic.  Accumulation of fat mass in 
humans and animals depends on balancing caloric intake and energy expenditure.  
Although there currently is no effective treatment for obesity, studies have provided 
convincing evidence that arginine and conjugated linoleic acid (CLA) independently 
reduce fat mass in animal species (1,2).  Because, individually, both arginine and CLA 
have been shown to reduce fat mass, our objective was to document the interaction 
between arginine and CLA on carcass composition in rodent species.  This has never 
been documented before, and the information gained from this study will be used in 
future studies with bovine and porcine species and humans. This study will give us the 
information needed to produce livestock efficiently and to produce a high-quality 
product.  For humans, this information will help us begin to treat obesity and associated 
diseases such as type-II diabetes and cardiovascular disease.   
 The objectives for this study were: 1) to determine how rat adipose tissue 
responds to arginine and/ or CLA treatments during growth; 2) establish if arginine 
supplementation will affect apparent hepatic stearoyl CoA desaturase-1 (SCD1) activity; 
and 3) document the effects of arginine and CLA on adiposity and adipose tissue 
metabolism. 
In rat species, brown adipocytes can be found within white adipose tissue.  
Promoting mitochondrial biogenesis in brown adipocytes may be the mechanism by  
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which dietary arginine works to reduce fat mass in rodent species.  Based on what is 
known about arginine and CLA, we hypothesized that adding dietary arginine and CLA 
will reduce fat mass and increase lean muscle gain in rats. 
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LITERATURE REVIEW 
Nitric oxide (NO) 
  
Previous studies have shown that dietary supplementation of arginine increases 
brown fat mass (1).  Nitric oxide is an important regulator of metabolism.  Because NO 
is a small, hydrophilic gas molecule, it is able to diffuse into cells and act on its target 
molecules via cGMP-dependent pathways.  NO regulates vascular tone, 
neurotransmission, immunity, and overall homeostasis.  L-Arginine is the precursor for 
NO and is converted to NO by nitric oxide synthase (NOS).   NOS has three isoforms: 
nNOS, iNOS, and eNOS.  nNOS was first identified in neuronal tissue (3,4,5).  iNOS 
has been shown to be induced by both cytokines and lipopolysaccharides (4,5),  and 
eNOS was identified in vascular endothelial cells (4,5).  Although nNOS and eNOS 
produce relatively small amounts of NO (4,5), iNOS can be induced to produce high 
amounts of NO (4,5).  All of the NOS isoforms may be induced under stimuli via 
transcriptional and translational pathways (6).   
Several studies have suggested that insulin-sensitive tissues are key sites for NO 
synthesis.  These include skeletal muscle, heart, kidneys, liver, and the brain. The NOS 
isoforms are mainly found in the sarcolemma, sarcoplasm, sarcoplasmic reticulum, and 
mitochondria of muscle fibers (7).  In myocytes, the expression of NOS is regulated by 
factors such as fiber type, contraction, developmental stage, and the pathological state 
(8,9,10).  Two of the isoforms, eNOS and iNOS, are expressed in brown adipose tissue.  
However, these two isoforms appear to be absent in white adipose tissue (11,12).  In the 
liver, eNOS is distributed uniformly.  On the other hand, iNOS is primarily found in the 
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cytoplasm of periportal hepatocytes (13).  The compartmentalization of these NOS 
isoforms may be one way in which NO synthesis is regulated. 
NOS synthesis by iNOS and obesity 
 An increase in the expression of iNOS and an overproduction of NO has been 
linked to obesity.  In genetically obese rats, for example, iNOS expression in adipose 
tissue and skeletal muscle was higher than lean, non-obese wild-types (14,15).  By 
treating the obese rodents with an iNOS inhibitor, insulin sensitivity was improved, thus 
preventing diet-induced obesity. 
 Recently, it was demonstrated that dietary arginine reduced adiposity in Zucker 
diabetic fat (ZDF) rats (16).  These rats genetically resemble human Type II diabetics.  
After a 10-wk treatment period, the rats fed 1.25% arginine in drinking water had 25% 
less epididymal fat and 45% less abdominal fat than those rats given alanine 
(isonitrogenous control) in their water.  In addition, serum levels of arginine and NO 
derivatives increased significantly in the arginine-fed rats.  These results suggested that 
dietary arginine was effectively metabolized to citrulline, yielding NO.  This study also 
showed that the inhibition of NO synthesis resulted in increased triglyceride levels and 
body fat.   
 Arginine has been shown to enhance several genes that are responsible for fatty 
acid and glucose oxidation, such as PGC-1α.  Arginine increases the expression of PGC-
1α (16), which is a regulator of oxidative phosphorylation.  Therefore, an increase in the 
expression of PGC-1α could have caused the decrease in fat deposition.  Arginine 
decreased stearoyl CoA desaturase (SCD1) gene expression in the liver as well.   
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Stearoyl CoA desaturase 
Stearoyl CoA desaturase (SCD) is a ∆9 desaturase that catalyzes the synthesis of 
monounsaturated fatty acids from saturated fatty acyl-CoA.  The favored substrates of 
SCD are palmitate (16:0) and stearate (18:0).  Their respective products, especially 
oleate (18:1 n-9), are favored substrates for triglyceride synthesis.  By decreasing hepatic 
SCD 1 expression, very low density lipoprotein (VLDL) output from the liver will also 
decrease, potentially resulting in a decrease in adipose tissue accumulation. 
Conjugated linoleic acid  
Studies also have provided convincing evidence that conjugated linoleic acid 
(CLA) decreases body fat.  CLA decreases uncoupling protein-1 (UCP 1) expression in 
brown adipose tissue (17). UCP 1 is an uncoupling protein found only in brown adipose 
tissue.  A UCP 2 isoform can be found in white adipose tissue (17).  Like NO, CLA 
decreases SCD gene expression in the liver and decreases PPARγ2 expression in adipose 
tissue (18,19,20).  PPARγ2 is a master gene that is found in brown and white adipose 
tissue.  It acts to increase SCD expression and increase fatty acid synthesis (18,19,20).  
By decreasing PPARγ expression, SCD expression and fatty acid synthesis also is 
decreased, which results in a decrease in fat deposition. 
Recently, Corino et al. (21) demonstrated that CLA reduced adiposity in market 
weight pigs.  The pigs fed CLA had a lower adipocyte area (i.e., smaller adipocytes) than 
the control group.  Dietary CLA, especially trans-10, cis-12 (t10,c12) CLA reduces 
carcass adiposity in several species (22,23).  In addition, mixed isomers of CLA 
depressed 3T3-L1 preadipocyte proliferation and [3H] thymidine incorporation into 
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DNA (24).  Adams et al. (25) and Corino et al. (21) similarly reported that CLA reduced 
the percentage of proliferating cells in subcutaneous adipose tissue of pigs.  Although 
CLA caused only small reductions in adipocyte volume, it strongly depressed SCD gene 
expression and catalytic activity (26).  The pigs used by Smith et al. (26) and Adams et 
al. (25) were weanling pigs; CLA has been shown to more strongly depress adiposity in 
market-weight pigs (21, 27).  The t10,c12 CLA isomer prevents lipid filling of 
preadipocytes by decreasing PPARγ gene expression (18,19,20,28).  
Several studies have addressed the effects of CLA on brown adipose tissue gene 
expression.  Feeding mixed isomers of CLA to rats had no effect on expression of any of 
the UCPs in brown or white adipose tissues, although it reduced adipose tissue weights 
(17).  Conversely, mice fed CLA had increased expression of UCP 1 in brown adipose 
tissue, and they had increased UCP 2 gene expression in both brown and white adipose 
tissues (17).  Thus, in rats at least, the expression of UCPs is not necessary for the 
reduction in adiposity caused by CLA.  Takahasi et al. (2) also demonstrated that feeding 
mixed isomers of CLA depressed the weights of white and interscapular brown adipose 
tissues.  CLA decreased PPARγ mRNA, but it increased UCP 2 in brown adipose tissue.  
CLA also depressed PPARγ mRNA in white adipose tissue of one strain of mice (2).  
Rodriguez et al. (29) reported that t10, 12 CLA depressed UCP 1 gene expression in 
cultured brown adipocytes, whereas c9,t11 CLA had the opposite effect.  This presents 
the possibility that feeding mixed isomers of CLA may actually reduce adiposity by 
stimulating thermogenesis, but this has not been documented in an animal system. 
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Observations from these studies led to the possibility that NO and CLA can have 
either complementary or antagonistic effects on adiposity.  Several investigators have 
demonstrated an interaction between CLA and NO.  Yu et al. (30) and Iwakiri et al. (31) 
reported that CLA decreased iNOS gene expression in murine macrophages.  Yang and 
Cook (32) demonstrated that both c9,t11 and t10,c12 CLA isomers depressed NO 
synthesis in macrophages from CLA-fed mice, and Eder et al. (33) demonstrated that 
both CLA isomers decreased iNOS gene expression in human aortic endothelial cells.  
To date, there are no published reports of the interaction between CLA isomers and NO 
(or arginine) on mitochondrial biogenesis in adipose tissue metabolism. 
Recently, t10,c12 CLA was shown to reduce lipoprotein lipase, the enzyme 
responsible for the breakdown of triglycerides, while increasing lipogenic enzyme 
activities in hamsters (34).  In addition, the transcriptional factors that regulate lipogenic 
enzymes were also studied.  These include SREBP-1a, SREBP-1c, and PPARγ.  CLA 
was shown to increase the expression of all three transcriptional factors, even though 
there was a reduction in acetyl CoA carboxylase and fatty acid synthase levels (34).   
There is also convincing evidence that CLA differentially alters fatty acid 
composition in porcine adipose tissue (26,35,36).  Dietary supplementation of CLA 
causes a significant increase in myristic (14:0) and palmitic acids while reducing 
arachidonic acid.  This suggests that CLA alters the activities of the ∆5, ∆6, and ∆9 –
desaturases.   
Based on what is currently known about CLA and arginine, we hypothesized that 
feeding a dietary combination of CLA and arginine would reduce fat mass by increasing 
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oxidation of metabolic substrates while depressing synthesis of lipids in adipose tissue 
and liver. 
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MATERIALS AND METHODS 
The overall objective of this study was to document the interrelationships 
between adipose tissue and liver metabolism and adipogenesis in rat species. Therefore, 
the response of rat liver and epididymal adipose tissue to exposure to arginine and mixed 
isomers of CLA during growth was characterized.  Specifically, we wanted to determine 
whether arginine treatment would stimulate the rate of oxidation of glucose and 
palmitate in rat adipose tissue.  The effects of arginine and/or CLA on plasma and 
hepatic fatty acids were measured to provide an estimate of hepatic SCD1 activity. 
Animals and diets 
For this study, 24 male Sprague Dawley rats (8 wk old) were obtained from a 
commercial source and were growing rats.  Beginning at 9 wk of age, the rats received 
drinking water containing 2.55% alanine or 1.25% arginine and fed a casein-based semi-
purified diet containing 1.5% canola or mixed isomers of CLA for 5 wk (Table 1, 2).  
The dietary treatment lasted for 5 wk.  The study was a 2 x 2 factorial design, with two 
levels of arginine (0 and 1.5%) and two levels of CLA (0 and 1.5%).  The treatment 
groups were: 
•Control rats (n = 6), fed 2.55% L-alanine (isonitrogenous control) plus 1.5% canola 
(lipid control). 
•Arginine rats (n = 6), fed 1.25% L-arginine plus 1.5% canola. 
•CLA rats (n = 6), fed 2.55% L-alanine plus 1.5% mixed isomers of CLA 
(triacylglycerol preparation). 
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•Arginine plus CLA rats (n = 6), fed 1.25 % L-arginine plus 1.5% mixed isomers of    
CLA. 
Canola was used as a lipid control because it is food grade and its melting point 
is similar to the triacylglycerol preparation of CLA.  Both diets had 20% protein, 70% 
carbohydrate, and 4% fat (Table 1).  Food and water intake was measured on a daily 
basis and body weight was measured every 3-4 d. 
Sample collection 
After 5 wk of treatment and approximately 12 h after last feeding, the rats were 
terminated using a CO2 gas chamber.  Final body weights were taken prior to 
termination and empty carcass weight was taken following termination.  The liver, 
adipose tissue, and viscera were all dissected and weighed. Samples of liver and adipose 
tissue were stored at -80ºC.  The soleus and extensor digitorum longus muscles were 
also dissected, weighed, and stored at -80ºC.  Fresh liver and epididymal tissues were 
collected at harvest to measure metabolism in vitro.  Blood was collected by 
exsanguination and plasma was separated and stored at -80ºC for analysis of amino acid 
and fatty acid concentrations. 
Lipogenesis 
Lipogenesis was measured using the fresh adipose tissues and liver collected at 
harvest. Two-hour in vitro incubations were conducted in culture flasks with liver or 
epididymal adipose tissue samples (37,38).  Samples (approximately 100 mg) were 
incubated in flasks containing 5 mM glucose, 0.75 mM palmitate, 10 mM Hepes buffer, 
50 ng/mL insulin, and either 1 µCi [U-14C]glucose or 0.5 µCi [1-14C]palmitate in Krebs-
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Henseleit buffer.  Vials were gassed for 1 min with 95% O2:5% CO2 and incubated for 2 
h in a shaking water bath at 37°C.  At the end of the incubation period, reactions were 
terminated by addition of 0.5 mL of 2 N H2SO4, and flasks were shaken for an additional 
2 h.  
Neutral lipid extraction 
 Neutral lipids in the adipose tissues were extracted using the Folch et al. (39) 
procedure, evaporated to dryness, and resuspended in 10 mL of scintillation cocktail. 
The radioactivity in the lipid was counted with a liquid scintillation counter (Beckman 
Instruments, Palo Alto, CA).   
Substrate oxidation 
 The production of CO2 was used as an indicator of glucose and fatty acid 
oxidation.  Liver and epididymal adipose tissues were collected at harvest and incubated 
as described above.  Hanging center wells were suspended in 25-mL flasks containing 3 
mL medium. Filter paper was placed inside the hanging center well and after 2 h 
incubation, the filter paper was soaked with NaOH.  At the same time, 0.5 mL of 2N 
H2SO4 was injected into the medium. The flasks were shaken for an additional 2 h to 
allow the release of CO2 from the medium.  The NaOH trapped the CO2 released from 
the medium.  The filter paper was then placed in scintillation vials, 1 mL water and 10 
mL scintillation fluid were added, and the samples were counted on a liquid scintillation 
counter. 
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Fatty acid analysis 
Fatty acid composition in liver and plasma was determined using a fatty acid 
methylation procedure (FAME).  Fatty acids were extracted using Folch et al (38) 
methods.  Methylation was done as described by Morrison and Smith (39).  FAME were 
analyzed using a Varian Gas Chromatograph (model CP-3800 fixed with a CP-8200 
autosampler, Varian Inc., Walnut Creek, CA).  Identification of sample fatty acids were 
made by comparing the relative retention times of FAME peaks from samples with those 
of standards (reference standard GLC-68B, Nu-Chek Prep, Elysian, MN).  Separation of 
FAME was accomplished on a fused silica capillary column CP-Sil88 [100 m x 0.25 mm 
(i.d.)] (Chrompack Inc., Middleburg, The Netherlands).  Helium was the carrier gas (1.2 
mL/min).  After 32 min at 180ºC, oven temperature was increased at 20ºC/min to 225ºC 
and held for 13.75 min.  Total run time was 48 min. Injector and detector temperatures 
were at 270 and 300ºC, respectively.  
Amino acids 
Plasma amino acids were analyzed using high performance liquid 
chromatography.   (The HPLC apparatus and precolumn derivatization of amino acids 
with o-phthaldialdehyde were as previously described (40).  Amino acids (except proline 
and cysteine) were separated on a Supelco 3-µm reversed-phase C18 column (4.6 x 150 
mm, I.D.) guarded by a Supelco 40-µm reversed-phase C18 column (4.6 x 50 mm, I.D.).  
The HPLC mobile phase consisted of solvent A (0.1 mmol/L sodium acetate-0.5% 
tetrahydrofuran-9% methanol; pH 7.2) and solvent B (methanol), with a combined total 
flow rate of 1.1 mL/min.  A gradient program with a total running time of 49 min 
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(including the time for column regeneration) was developed for satisfactory separation 
of amino acids (0 min, 14% B; 15 min, 14% B; 20 min, 30% B; 24 min, 35% B; 26 min, 
47% B; 34 min, 50% B; 38 min, 70% B; 40 min, 100% B; 42 min, 100% B; 42.1 min, 
14% B; 48.5 min, 14% B).  Proline was measured by an HPLC method involving 
oxidation of proline to 4-amino-1-butanol and precolumn derivatization with o-
phthaldialdehyde.  For cysteine analysis, 100 µL sample was mixed with 50 µL of 50 
mM iodoacetic acid (an alkylating agent) for 5 min at room temperature, to convert 
cysteine to S-carboxymethylcysteine.  The latter then reacts with o-phthaldialdehyde to 
form a highly fluorescent derivative.  For cystine analysis, 100 µL sample was mixed 
with 100 µL of 28 mM 2-mercaptoethanol (a reducing agent) for 5 min at room 
temperature, to convert cystine to cysteine, and the latter was then analyzed as described 
above.  Amino acids were quantified on the basis of authentic standards (Sigma 
Chemicals, St. Louis, MO) using the MillenniumTM workstation (Waters Inc., Milford, 
MA) (40). 
Adipose tissue cellularity 
Approximately 25 mg of frozen adipose tissue was thinly sliced using a scalpel 
blade.  The exact weights of the tissue samples were recorded.  Samples were kept on ice 
at all times.  The samples were transferred to scintillation vials and rinsed three times 
with 0.154 mol/L NaCl.  In the hood, 0.6 mL of 50 mM collidine-HCl buffer was added.  
One milliliter of 3% osmium tetraoxide was added, and samples incubated in a water 
bath at 37ºC for 72 h.  The osmium was removed and the samples were rinsed with 0.7% 
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NaCl.  Triton X-100 was added and samples were swirled gently to separate the 
adipocytes.  Adipocytes were counted with a two-chamber Neubauer hemocytometer.   
Statistical analysis 
Data was analyzed using the SuperNova (Abacus concepts, Berkeley, CA) 
statistical analysis program.  Two way analysis of variance was used at a significance 
level of P < 0.05, and the main effects of fatty acid, amino acid, and their interaction 
were analyzed. 
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RESULTS 
Food and water intake 
Rats that were fed arginine plus CLA had a higher daily intake of food (P = 0.02, 
Table 3).  Rats fed arginine plus CLA had a higher average daily gain than rats fed only 
arginine or CLA (Table 3), but the difference was not significant. As expected, 
supplemented intake of alanine was significantly higher in the alanine-fed rats, whereas 
arginine intake was greater in the arginine-fed rats. 
Final tissue weights 
Final body weight was measured just prior to termination (Table 3).  Although 
there was no significant arginine x CLA interaction (P = 0.83), arginine and CLA 
individually increased final body weight (P = 0.04 and 0.009).  CLA tended to reduce 
abdominal fat mass (P = 0.08), but arginine had no significant effect on abdominal fat 
mass (P = 0.34; Table 4). Ratios of abdominal fat:final body weight and abdominal 
fat:empty carcass weight also were calculated.  For the abdominal fat:final body weight 
ratio, there was a significant CLA effect (P = 0.05; Fig.1). However, there was no 
significant arginine x CLA interaction (P = 0.14) on the abdominal fat:final body weight 
ratio.  The ratio of abdominal fat:empty carcass weight showed a similar trend, with 
CLA decreasing the ratio (P = 0.03).  Ratios of epididymal fat:final body weight and 
epdidymal fat:shrunken body weight showed no significant arginine x CLA interaction 
(P = 0.49 and 0.52, respectively).  There also were no CLA or arginine effects on these 
ratios (P = 0.52 and 0.51; Fig. 2).  There was no significant arginine x CLA effect on 
final soleus and EDL muscle weights (P = 0.58 and 0.68, respectively; Table 5).  Finally, 
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there was no significant arginine x CLA interaction on final liver or viscera weight (P = 
0.68 and 0.80, respectively).  CLA tended to increase liver weight (P = 0.09; Table 5). 
Liver fatty acids 
 CLA significantly increased saturated fatty acids such as myristic acid and  
 
palmitic acid (P = 0.03 and 0.04, respectively; Table 6).  There was no significant  
 
arginine x CLA effect (P = 0.50, 0.54) on hepatic myristic and palmitic acid  
 
concentrations. CLA significantly decreased monounsaturated fatty acids such as  
 
myristoleic acid and palmitoleic acid (P = 0.009, 0.007).  There was not a significant  
 
arginine x CLA effect (P = 0.56, 0.24) on myristoleic and palmitoleic acid  
 
concentrations.  CLA did decrease the ratio of hepatic palmitoleic acid:palmitic acid  
 
(Fig.4). CLA did not have a significant effect on stearic acid (P = 0.59).  However, CLA  
 
significantly decreased the concentration of oleic acid (P = 0.0001).  CLA also  
 
significantly decreased the oleic/stearic acid ratio (P = 0.0005).  As expected, CLA  
 
supplementation also significantly increased cis-9,trans-11 CLA concentrations (P =  
 
0.0001; Table 6). 
 
Plasma fatty acids 
 
Although there was no arginine x CLA interaction observed for plasma fatty  
 
acids, CLA significantly changed saturated and unsaturated fatty acid concentrations  
 
(Table 7).  CLA significantly increased palmitic acid and stearic acid (P = 0.03 and  
 
0.005, respectively).  CLA did not have a significant effect on plasma  
 
oleic acid concentration (P = 0.49).  However, CLA did tend to decrease the plasma  
 
oleic/stearic acid ratio (P = 0.07 ).  CLA also significantly decreased eicosapentaenoic  
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(EPA) acid (P = .01).  As predicted, CLA significantly increased cis-9,trans-11 CLA  
 
concentration (P = .04; Table 7). 
 
Lipid synthesis in liver and epididymal adipose tissue 
 
 Lipid synthesis was measured using glucose and palmitate as substrates.  Glucose 
can be used to synthesize the glycerol backbone of triacylglycerols and phospholipids or 
for fatty acid synthesis.  Palmitate can be used in the synthesis of neutral lipids or 
phospholipids.  In the liver, neither arginine nor CLA supplementation significantly 
affected conversion of glucose to fatty acids (P = 0.44).  There also were no significant 
arginine or CLA effects on the conversion of palmitate to lipids (P = 0.13). 
 In epididymal adipose tissue, arginine plus CLA supplementation decreased the 
rate of lipid synthesis from glucose (P = 0.20).  In addition, arginine tended to decrease 
the rate of lipid synthesis from palmitate (P = 0.09).  In this study, epididymal adipose 
tissue was the major site of lipid synthesis from glucose and palmitate (Table 8). 
Adipose tissue cellularity 
 Cellularity was measured using the osmium fixation method as an indicator of  
 
the effects of arginine and/or CLA supplementation on adipocyte size and number.  A  
 
larger number of cells/area correlates to a decrease in cell size.  There were no  
 
significant arginine or CLA effects on adipocytes/100 mg adipose tissue (P = 0.63;  
 
Table 9).   
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CO2 production 
 
 The production of CO2 was used as an indicator of glucose and fatty acid 
oxidation (Table 9).  In liver tissue with glucose as the substrate, there was no significant 
arginine x CLA interaction (P = 0.48).  Arginine supplementation tended to increase 
hepatic CO2 production from glucose (P = 0.06).  With palmitate as the substrate, there 
was also no significant arginine x CLA interaction (P = 0.33).  For epididymal adipose 
tissue CO2 production, there was no significant arginine x CLA interaction with either 
glucose or palmitate (P = 0.99 and 0.92, respectively).  When rates were expressed as 
nmol CO2/106 cells, there also was no significant arginine x CLA interaction with either 
glucose or palmitate as substrate (P = 0.56 and 0.78, respectively; Table 9). 
Amino acids 
 
   A significant arginine x CLA interaction was seen for reducing arginine, 
alanine, and ornithine levels (P = 0.05, 0.002, and 0.04 respectively).  Interestingly, 
these amino acids behaved in the same manner across treatment groups.  The decreased 
plasma levels of these amino acids suggest that arginine plus CLA strongly stimulated 
protein synthesis. The levels of branched chain amino acids valine, isoleucine, and 
leucine were all depressed in the treatment groups that included CLA.  This suggests that 
protein turnover in the skeletal muscle was reduced, leading to an increase in lean 
muscle mass.  CLA also reduced plasma levels of glutamine, citrulline, tyrosine, and 
phenylalanine.   
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DISCUSSION 
 Researchers have been trying to find ways to effectively treat obesity and prevent 
diseases associated with obesity such as type II diabetes and cardiovascular disease.  
This study examined the effects of arginine and CLA supplementation on lipid 
metabolism in rats.  The results from this study indicated that arginine plus CLA 
supplementation increased lean muscle mass, decreased abdominal fat mass, and 
increases glucose oxidation in the liver.  Arginine also doubled glucose and palmitate 
oxidation in epididymal adipose tissue, but this effect was not statistically significant.  
These findings suggest that arginine plus CLA supplementation may be an effective 
method for treating obesity while concomitantly increasing lean muscle mass. 
 The findings from this study with growing rats showed that arginine 
supplementation did not affect EDL or soleus muscle mass.  There are differences in 
muscle fiber type in these two muscles.  Bain et al. (41) reported that the rat soleus 
muscle has more oxidative fibers than the EDL muscle. It also demonstrated a higher 
catalase activity in the soleus muscle of rats (41).  Arginine may have different effects 
on different muscles, depending on the muscle fiber type.  In myocytes, the expression 
of NOS is regulated by factors such as fiber type, contraction, developmental stage, and 
the pathological state (6,7,8).  The increase in lean muscle mass with arginine plus CLA 
supplementation also may be, in part, due to the activation of the mammalian target of 
rapamycin (mTOR) pathway.  Chung et al. (42) found that supplementation of CLA 
altered human adipocyte morphology through the activation of the mTOR pathway, p70 
S6 ribosomal protein kinase, and S6 ribosomal protein.  Through the activation the 
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mTOR pathway and these ribosomal proteins, CLA supplementation may provide 
translational control of the expression of adipose differentiation-related protein (ADRP) 
and the transcriptional control of perilipin A.  Perilipin A is found on the outer surface of 
lipids and functions as a protective protein coat, and in order for lipolysis to occur, this 
protein must be removed.  With CLA supplementation, there was an increase in the 
removal of perilipin A to the cytosol, allowing the lipid droplet to undergo lipolysis (42).  
In addition, CLA also activates the mitogen-activated protein kinase kinase/extracellular 
signal-related kinase (MEK/ERK) pathway.  The activation of this pathway led to a 
decrease in mRNA levels of PPARγ, perilipin, glucose transporter 4, ADRP, lipoprotein 
lipase, and adiponectin (42).  These effects led to a decrease in the uptake of fatty acids 
and glucose, resulting in a decrease in cellular triglycerides (42).  Arginine has also been 
shown to activate the mTOR pathway (43).  These finding suggest that arginine and 
CLA may decrease fat mass and increase lean mass through activation of the mTOR 
pathway.  
Previous studies have shown that dietary supplementation of arginine increases 
brown fat mass (1).  Nitric oxide is an important regulator of metabolism.  Because NO 
is a small, hydrophilic gas molecule, it is able to diffuse into cells and act on its target 
molecules via cGMP-dependent pathways.  NO regulates vascular tone, 
neurotransmission, immunity, and overall homeostasis.  L-Arginine is the precursor for 
NO and is converted to NO by nitric oxide synthase (NOS).   NOS has three isoforms: 
nNOS, iNOS, and eNOS.  nNOS was first identified in neuronal tissue (3,4,5).  iNOS 
has been shown to be induced by both cytokines and lipopolysaccharides (4,5),  and 
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eNOS was identified in vascular endothelial cells (4,5).  Although nNOS and eNOS 
produce relatively small amounts of NO (4,5), iNOS can be induced to produce high 
amounts of NO (4,5).  All of the NOS isoforms may be induced under stimuli via 
transcriptional and translational pathways (6).   
Several studies have suggested that insulin-sensitive tissues are key sites for NO 
synthesis.  These include skeletal muscle, heart, kidneys, liver, and the brain. The NOS 
isoforms are mainly found in the sarcolemma, sarcoplasm, sarcoplasmic reticulum, and 
mitochondria of muscle fibers (7).  Two of the isoforms, eNOS and iNOS, are expressed 
in brown adipose tissue.  However, these two isoforms appear to be absent in white 
adipose tissue (11,12).  In the liver, eNOS is distributed uniformly.  On the other hand, 
iNOS is primarily found in the cytoplasm of periportal hepatocytes (13).  The 
compartmentalization of these NOS isoforms may be one way in which NO synthesis is 
regulated. 
Fu et al. (16) demonstrated that arginine supplementation significantly reduced 
epididymal and abdominal adipose tissue mass in ZDF rats.  Although there was a 
reduction in abdominal adipose tissue weight with arginine supplementation in our 
study, arginine did not have a significant effect on reducing epididymal adipose tissue.  
These different results could be due to the differences in lean vs. obese rats.  Fu et al 
(16) used Zucker diabetic rats, which genetically resemble type II diabetes. Sprague 
Dawley rats, which are not genetically obese, were used in this study.  The rats used by 
Fu et al. (16) were fed for a longer period of time (10 wk), while the rats in this study 
were fed for 5 wk.  A longer feeding period may have resulted in more significant 
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arginine effects, especially in epididymal adipose tissue.  Finally, the Zucker diabetic 
rats were fed a higher fat diet (6%), while the rats in this study were fed a diet that was 
4% fat.  The differences in diet also may have contributed to the different results seen in 
these two studies. 
 With arginine plus CLA supplementation, plasma arginine concentrations 
decreased.  In addition, the plasma concentrations of branched chain amino acids also 
were decreased by the supplementation of arginine and/or CLA.  Because branched 
chain amino acids are deaminated in skeletal muscle (44), these findings suggest that 
arginine and CLA increase protein synthesis and/or decrease protein turnover in skeletal 
muscle, which would explain the increase in lean mass that was observed.  Gluatamine 
and alanine, which is produced by the skeletal muscle, decreased with arginine and CLA 
supplementation.  This indicates less nitrogen flux from muscle and/or the intestine. 
 Ntambi et al. (45) reported that supplementation of CLA reduced hepatic SCD1 
gene expression in mice.  With a decrease in hepatic SCD1 activity, liver and plasma 
monounsaturated fatty acid concentrations are reduced.  This is consistent with our 
findings, as rats that were fed CLA had decreased liver monounsaturated fatty 
acid:saturated fatty acid ratios (Fig. 3,4) and plasma oleic:stearic acid ratios.  This ratio 
is used as an index of hepatic SCD1 activity (22,36).  With a decrease in hepatic SCD1 
activity, there also is a decrease in triglyceride levels, a decrease in VLDL output from 
the liver, and a decrease in abdominal fat mass.  Arginine also has been shown to 
decrease hepatic SCD1 activity (16).  Our findings are consistent with these studies, 
because rats that were fed arginine plus CLA had the largest decrease in 
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monounsaturated/saturated fatty acid ratio and the largest decrease in abdominal fat 
mass. 
 Glucose oxidation was increased in the liver with arginine supplementation.  The 
production of CO2 from glucose is a measure of mitochondrial activity, specifically 
pentose cycle and TCA cycle activity.  There was not, however, a significant effect of 
arginine or CLA supplementation on palmitate oxidation.  The measurement of CO2 
production from palmitate is an indicator of TCA cycle activity.  With palmitate, there 
was no apparent increase in mitochondrial activity.  In epididymal adipose tissue, there 
was no significant effect of arginine or CLA on oxidation of glucose or palmitate, even 
though rates of CO2 production were twice as high in arginine rats. We cannot rule out 
the possibility that mitochondrial activity in epididymal adipose tissue is elevated by 
arginine supplementation.  Clearly, CLA had no effect on glucose or palmitate oxidation.
 Further studies on arginine plus CLA supplementation are needed in order to 
better understand the effects of arginine and CLA effects on lipid metabolism across 
different species.  This study did provide exciting evidence that arginine plus CLA 
supplementation has an effect on hepatic and adipose tissue lipid metabolism and may 
prove beneficial in future studies. 
 
 
 
 
 
 
 24
CONCLUSION 
 In conclusion, the results from this study show that both arginine and CLA have 
significant effects on lipid metabolism in both liver and adipose tissues.  Surprisingly, 
the combination of arginine plus CLA also promoted lean muscle mass.  The results 
from this study may be beneficial in developing a treatment for obesity in both humans 
and animals.  This could help improve overall human health and increase productivity in 
livestock production.  Further studies should be done in order to better understand 
effects of arginine and CLA on adiposity in livestock species and humans. 
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APPENDIX 
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Figure 1.   Abdominal adipose tissue:empty carcass weight ratios of rats fed arginine 
CLA, or a combination of arginine and CLA over a 5 wk period. 
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Epididymal/Empty carcass weight
 
 
 
Figure 2.   Epididymal adipose tissue:empty carcass weight ratios of rats fed arginine, 
CLA, or a combination of arginine and CLA over a 5 wk period. 
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Figure 3.  Ratio of hepatic oleic acid:stearic acid of rats fed arginine, CLA, or a 
combination of arginine and CLA over a 5 wk period. 
 
 
 33
 
 
 
Figure 4.  Ratio of hepatic palmitoleic acid:palmitic acid in rats fed arginine, CLA, or a 
combination of arginine and CLA over 5 wk period. 
 
 
 
 
 
 
 
 
 
 
 
0 
0.02 
0.04 
0.06 
0.08 
0.1 
0.12 
0.14 
0.16 
0.18 
0.2 
16:1:16:0 
Ratio(avg) 
Canola+ CLA+ Canola+ CLA+ 
Alanine Arginine Alanine Arginine
Treatment
Liver 16:1:16:0 Ratio
 
 34
 
 
 
 
 
 
        
 
4E-BP1 p70S6kinase 
Protein Synthesis S6-P 
PKB PI3K 
Amino Acids 
mTOR Proteolysis 
CLA Rapamycin Insulin 
 
Figure 5.   mTOR pathway. 
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Table 1. Composition of diets fed to rats over a 5 wk period.
    D12450B and D06101401-02  
 D12450B  D06101401 (CLA diet)  
DO6101402 
(Canola diet) 
                               
% gm  kcal gm kcal  gm kcal 
Protein 19.2 20 19 20  19 20
Carbohydrate 67.3 70 66.3 70  66.3 70
Fat 4.3 10 4.2 10  4.2 10
Total 90.8 100 89.4 100  89.4 100
kcal/gm 3.85  3.79   3.79  
        
Ingredient gm kcal gm kcal  gm kcal 
Casein, 80 Mesh 200 800 200 800  200 800
L-Cystine 3 12 3 12  3 12
        
Corn Starch 315 1260 315 1260  315 
126
0
Maltodextrin 10 35 140 35 140  35 140
Sucrose 350 1400 350 1400  350 
140
0
        
Cellulose, BW200 50 0 50 0  50 0
        
Soybean Oil 25 225 25 225  25 225
Lard 20 180 20 180  20 180
        
Mineral Mix 
S10026 10 0 10 0  10 0
DiCalcium 
Phosphate 13 0 13 0  13 0
Calcium Carbonate 5.5 0 5.5 0  5.5 0
Potassium Citrate, 
1H20 16.5 0 16.5 0  16.5 0
        
Vitamin Mix 
V10001 10 40 10 40  10 40
Choline Bitartrate 2 0 2 0  2 0
        
CLA, Calrinol G-80 0 0 16 0  0 0
Canola Oil 0 0 0 0  16 0
Total 1055.05 4057 1071.05 4057  1071.05 
405
7
 
 Table 2.  Fatty acid composition of diets fed to rats over 5 wk period. 
 
 
Diet 14 0 16 0 16 1 18 0 18 1 18 1 
c11 
18 2 18 3 c9t11 t10c12 20 1 20.4 
Canola     0.6516 14.5997 0.7172 5.635 37.7938 2.2418 33.6919 4.6505  
CLA 0.4367 13.141 0.6801 6.4218 26.445 1.6133 30.9271 2.7718 5.5246 5.5279 6.1021 .4091
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 Table 3. Weekly body weights, food intake, and alanine/arginine intake of rats fed arginine, conjugated linoleic acid 
(CLA) or a combination of arginine plus CLA for 5 wk.1 
  
  Alanine   Arginine  Pooled  P-values  
Item Canola CLA Canola CLA SEM FA2 AA   FA xAA
Final body weight, g 424.7 442.1 437.3 457.5 3.79 0.009 0.04 0.83 
Shrunken body weight, g 365.9 372.8 371.6 387.9 3.19 0.06 0.09 0.42 
Body weight gain, g/d 1.74          1.40 1.17           1.73           0.17         0.74 0.72   0.20 
Food intake, g/d           34.0        35.4           35.8         37.9         0.44   0.02  
Supplemented alanine 0.87          0.90 0 0     
 intake, g/d 
  
Supplemented 0          0 0.54            0.58            
arginine intake, g/d         
1Data are means for 3 cages per treatment group, 2 rats per cage.  Alanine and arginine intakes were based on calculated 
water intake.  
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect. 
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 Table 4. Tissue weights and weight ratios from rats fed arginine, conjugated linoleic acid (CLA) or a combination of 
arginine plus CLA for 5 wk.1 
  
  Alanine   Arginine  Pooled  P-values  
Tissue  Canola  CLA Canola CLA SEM FA2 AA FA xAA
Abdominal adipose tissue, g            3.22   3.13           3.38 2.40           0.16 0.08 0.34  0.14 
Abdominal/final body weight         0.007 0.007 0.008 0.005               0.0004 0.05 0.26 0.14 
Abdominal/shrunken body weight   0.009 0.008 0.009 0.006    0.0004 0.03 0.19 0.12 
Epididymal adipose tissue, g           5.35        4.53 4.53 4.73 0.32            0.66          0.66        0.46 
Epididymal/final body weight        0.009 0.010 0.010 0.010 0.36 0.52 0.42 0.49 
Epididymal/shrunken body weight  0.014 0.012 0.012 0.012 0.004 0.51 0.53 0.52  
1Data are means for 6 animals per treatment group.  
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect. 
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 Table 5. Final tissue weights of rats fed arginine, conjugated linoleic acid (CLA) or a combination of arginine plus CLA 
for 5 wk.1
  
  Alanine   Arginine  Pooled  P-values  
Tissue/ Canola CLA Canola CLA SEM FA2 AA FA x AA
Liver, g 15.2          15.9 14.7          15.8 0.251         0.09 0.56   0.68 
Viscera, g 28.0           29.5 28.4           29.3 0.566         0.32 0.94   0.80 
Soleus3, g 0.343           0.327 0.306           0.307 0.008         0.64 0.89   0.58 
EDL3, g 0.329           0.314 0.340           0.335 0.006         0.42 0.19  0.68 
 
1Data are means for 6 animals per treatment group units are in grams. 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect. 
3Weights are two muscles 
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 Table 6. Liver fatty acids (g/100 g total fatty acids) of rats fed arginine, conjugated linoleic acid (CLA) or a combination of arginine plus CLA 
for 5 wk.1
  
  Alanine   Arginine  Pooled  P-values  
Fatty Acid Canola CLA Canola CLA SEM FA2 AA  FA x AA
Myristic acid 0.89         1.05 0.98 1.06 0.028          0.03 0.36    0.50 
Myristoleic acid 0.073   0.056 0.073 0.05 0.004          0.009 0.60    0.56 
Palmitic acid  18.36         20.08 19.17 20.12 0.329          0.04 0.50    0.54 
Palmitoleic acid 3.41         2.91 3.82 2.66 0.158          0.007 0.77 0.24 
Margaric acid 0.229 0.227 0.208 0.227 0.006 0.48 0.37 0.37 
trans-10 Heptadecenioic acid 0.159 0.152 0.152 0.153 0.005 0.78 0.82 0.75 
Stearic acid 3.08         3.19 3.03 3.42 0.079          0.12 0.59 0.40 
trans Vaccenic acid 0.14         0.40 0.13 0.42 0.033          0 .0001 0.90    0.75 
Oleic acid 28.99         25.06 29.94 25.84 0.480          0.0001 0.08    0.85 
Cis-11 Oleic acid 3.74 3.27 3.95 3.48 0.069 0.0001 0.04 0.98 
Linoleic acid 34.70         33.11 32.63 31.79 0.536          0.26 0.12    0.72 
Cis-9, trans11 CLA 0.07         2.46 0.11 2.98 0.293          0.0001 0.19    0.26 
trans-10,cis12 CLA 0.008         1.56 0.02    1.93 0.199          0.0001 0.27       0.29 
Linolenic acid 2.41         2.06 2.39             1.86 0.062          0.0001 0.20    0.29 
Arachidonic acid 0.615         0.535 0.438 0.407 0.049          0.58 0.14    0.80 
Eicosapentaenoic acid 0.039         0.020 0.025 0.02 0.004          0.11 0.32    0.46 
Docosahexanoic acid 0.15         0.103 0.083 0.057 0.015          0.20 0.05    0.71 
Oleic/stearic acid 9.46 8.01 9.93 7.73 0.281 0.0005 0.84 0.40 
1Data are means for 6 animals per treatment group. 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect.
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 Table 7. Plasma fatty acids (g/100 g total fatty acids) from rats fed arginine, conjugated linoleic acid (CLA) or a combination of 
arginine plus CLA for 5 wk.1
  
  Alanine   Arginine  Pooled   P-values  
Fatty Acid Canola CLA Canola CLA SEM FA2 AA     FA x AA 
Myristic 0.938 1.04 0.805 0.653 0.13 0.94 0.37 0.65 
Myristoleic 0.169 0.164 0.145 0.068 0.05 0.69 0.57 0.73 
Palmitic acid 21.3  23.2 20.8 21.9 0.35 0.03 0.14 0.52 
Palmitoleic acid 2.79 2.10 2.57 2.34 0.21 0.33 0.98 0.61 
Stearic acid 11.5  13.2 10.9 12.2 0.30 0.005 0.12 0.71 
trans-Vaccenic acid 0.27 0.922 0.153 0.232 0.182 0.34 0.29 0.45 
cis-9 Oleic acid 19.3  18.9 18.7 16.9 0.77 0.54 0.48 0.69 
cis-Vaccenic acid 3.16 2.33 3.18 2.96 0.14 0.62 0.24 0.26 
Oleic acid 19.88 17.51 19.40 17.51 0.77 0.49 0.49 0.67 
Linoleic acid 20.1  18.4 20.9 21.2 0.72 0.66 0.25 0.54 
cis-9,trans-11 CLA 0.0  0.686 0.326 0.876 0.14 0.04 0.36 0.81 
Linolenic acid 0.0  1.38 0.345 0.954 0.21 0.02 0.92 0.33 
Arachidonic acid 16.8  15.2 16.9 17.2 0.78 0.71 0.54 0.60 
Eicosapentaenoic acid 0.382 0.0 0.352 0.104 0.06 0.01 0.75 0.57 
Docasahexaenoic 1.59 1.30 1.71 1.52 0.09 0.19 0.35 0.78 
Oleic/stearic acid 1.69 1.44 1.72 1.40 0.07 0.07 0.99 0.80 
1Data are means for 6 animals per treatment group. 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect.  
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 Table 8. Lipogenesis in epididymal adipose tissue and liver from rats fed arginine, conjugated linoleic acid (CLA) or a 
combination of arginine plus CLA for 5 wk.1 
  
  Alanine   Arginine  Pooled  P-values  
Tissue/substrate Canola CLA Canola CLA SEM FA2       AA   FA x AA
Liver 
 Glucose/100 mg  1.34 1.34 1.26 1.12 0.19 0.87 0.71 0.87 
 Palmitate/100 mg 87.2 63.1 48.3 21.5  9.2 0.39 0.10 0.65 
Epididymal adipose tissue 
 Cells/100 mg      565,922          550,427 438,893          499,786 38,189 0.78 0.27 0.63 
 Glucose/100 mg 17.6 18.3 14.9 14.2 1.41 0.99 0.25 0.81
 Glucose/106 cells 35.4 34.3 63.1 28.7 6.1 0.14 0.35 0.16 
 Palmitate/100 mg 230.6 171.3 97.6 106.7 16.8 0.34 0.001 0.20 
 Palmitate/106 cells 416.9 279.2 279.5 236.7 31.4 0.22 0.09 0.58 
1Data are means for 6 animals per treatment group.  Rates are nmol substrate converted to lipid per 100 mg tissue or per 106 
cells (epididymal adipose tissue only). 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect.
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 Table 9. CO2 in epididymal adipose tissue and liver from rats fed arginine, conjugated linoleic acid (CLA) or a 
combination of arginine plus CLA for 5 wk.1 
  
  Alanine   Arginine  Pooled  P-values  
Tissue/substrate Canola CLA Canola CLA SEM FA2 AA     FA x AA
Liver 
 Glucose/100 mg 3.15 2.74 7.50 4.75 0.87 0.34 0.06 0.48 
 Palmitate/100 mg 7.33 17.11 6.61 7.93 1.20 0.21 0.26 0.33 
Epididymal 
 Glucose/100 mg 7.34 10.05 8.75 11.48 1.38 0.38 0.65 0.99 
 Glucose/106 cells 13.09 17.70 26.95 22.70 3.53 0.98 0.23 0.56 
 Palmitate/100 mg 4.55 8.26 7.88 12.19 1.81 0.21 0.25 0.92 
 Palmitate/106 cells 8.68 16.22 22.34 25.71 2.56 0.46 0.13 0.78 
1Data are means for 6 animals per treatment group.  Rates are nmol substrate converted to CO2 per 100 mg tissue or per 106 
cells (epididymal adipose tissue only). 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect
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 Table 10. Cells/epididymal adipose tissue depot in rats fed arginine, CLA, or a combination of arginine and CLA over a 
5 wk period. 
 
Treatment Group Cells/Epididymal adipose tissue 
Canola + alanine 30,300,000 
CLA + alanine 24,900,000 
Canola + arginine 19,900,000 
CLA + arginine 23,600,000 
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 Table 11. Plasma amino acids of rats fed arginine, conjugated linoleic acid (CLA) or a combination of arginine plus CLA for 5 wk.1 
  Alanine   Arginine  Pooled  P-values  
Amino Acid Canola CLA Canola CLA SEM FA2     AA   FA x AA 
ASN 69.8 54.5 61.2 41.9 3.93 0.03 0.18 0.80 
SER 210.4 161.3 211.9 143.2 11.44 0.01 0.72 0.67 
GLN 787.9 535.7 517.5 369.4 48.10 0.03 0.02 0.57 
GLY 192.3 145.3 171.9 128.3 8.84 0.01 0.28 0.92 
THR 243.4 176.7 238.7 166.0 12.52 0.007 0.75 0.90  
ALA 680.0 422.1 424.8 288.6 35.45 0.002 0.002 0.31 
TYR 92.7 59.9 72.3 48.9 4.96 0.004 0.09 0.61 
TRP 103.1 75.9 69.4 51.4 5.82 0.04 0.01 0.67 
MET 65.2 46.4 45.8 36.9 3.36 0.03 0.03 0.44 
VAL 226.3 148.7 136.7 107.3 11.29 0.008 0.001 0.21 
PHE 68.4 49.0 51.5 42.8 3.39 0.04 0.08 0.42 
ILE 111.3 71.6 71.4 50.6 5.84 0.004 0.004 0.36 
LEU 192.6 122.6 121.7 92.4 10.5 0.01 0.01 0.28 
CYS 188.5 191.0 169.2 182.0 6.74 0.59 0.32 0.72 
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 Table 11 continued 
  Alanine   Arginine  Pooled  P-values  
Amino Acid Canola CLA Canola CLA SEM FA2 AA FA x AA 
GLU 212.2 129.5 135.9 112.2 11.64 0.02 0.03 0.17 
HIS 109.7 77.6 93.0 72.5  3.97 0.0005 0.13 0.41 
CIT 74.4 58.8 73.3 52.8 3.83 0.02 0.64 0.75 
ARG 87.5 100.6 251.7 172.6 14.38 0.15 0.0001 0.05 
Beta-AlA 8.5 5.1 5.6 4.2 0.49 0.01 0.04 0.25 
TAU 400.4 262.8 263.1 268.3 20.70 0.10 0.10 0.08 
ORN 136.3 53.0 126.5 120.4 9.77 0.01 0.11 0.04 
ASP 21.6 14.04 19.9 17.7 1.62 0.15 0.76 0.42 
LYS 424.3 313.9 315.4 254.7 22.7 0.06 0.06 0.57 
1Data are means for 6 animals per treatment group.  Units are nmol/mL 
2FA, fatty acid effect (canola or CLA); AA, amino acid effect (alanine or arginine); FA x AA = interaction effect 
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